

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

KP-2

RRID:CVCL_3004

Type: Cell Line

Proper Citation

RRID:CVCL_3004

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3004

Proper Citation: RRID:CVCL_3004

Description: Cell line KP-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic carcinoma

Defining Citation: [PMID:2172194](#), [PMID:18380791](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KP-2

Synonyms: KP2

Cross References: BTO:BTO_0003550, CLO:CLO_0037107, EFO:EFO_0006621, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:615, BioSample:SAMN03472830, BioSample:SAMN03472944, BioSample:SAMN10988261, cancercellines:CVCL_3004, Cell_Model_Passport:SIDM00582, CGH-DB:175-1, CGH-DB:9370-4, Cosmic:918057, Cosmic-CLP:1298218, DepMap:ACH-000281, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298218, GEO:GSM887235, GEO:GSM888309, IARC_TP53:28361, JCRB:JCRB0181, LiGeA:CCLE_694, LINCS_LDP:LCL-1728,

PharmacoDB:KP2_783_2019, PRIDE:PXD030304, Progenetix:CVCL_3004, Wikidata:Q54900359

ID: CVCL_3004

Record Creation Time: 20220427T220707+0000

Record Last Update: 20260829T234425+0000

Ratings and Alerts

No rating or validation information has been found for KP-2.

No alerts have been found for KP-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer research, 86(8), 1868.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Nature communications, 16(1), 9996.

Campos AD, et al. (2025) A STAT3/integrin axis accelerates pancreatic cancer initiation and progression. Cell reports, 44(8), 116010.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. Cancer research, OF1.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. Science advances, 11(42), eadx0632.

Wang YP, et al. (2021) Malic enzyme 2 connects the Krebs cycle intermediate fumarate to mitochondrial biogenesis. Cell metabolism, 33(5), 1027.

Munekage E, et al. (2021) A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal

squamous cell carcinoma. Neoplasia (New York, N.Y.), 23(9), 939.